Compare AstraZeneca plc (AZN) vs Direxion Daily TSLA Bull 2X Shares (TSLL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
AstraZeneca plc vs Direxion Daily TSLA Bull 2X Shares — how do they compare? AstraZeneca plc trades at $167.12 (market cap $253.13B), while Direxion Daily TSLA Bull 2X Shares trades at $12.47. The key difference: AstraZeneca plc pays a 1.92% dividend while Direxion Daily TSLA Bull 2X Shares pays none, and AstraZeneca plc is trading nearer its 52-week high, Direxion Daily TSLA Bull 2X Shares nearer its low. Which is the better fit depends on your goals.
| AZN | TSLL | |
|---|---|---|
Market Cap | $253.13B | — |
Sector | Health | Leveraged / Inverse |
52-Week High | $209.48 | $23.03 |
52-Week Low | $137.44 | $10.29 |
Enterprise Value | $279.37B | — |
Dividend Yield | 1.92% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AstraZeneca (AZN) trades at $169.47, down 1.25% amid recent volatility following a Phase III trial failure for Wainua. The stock shows bearish technical signals with key support at $168 and resistance at $170. Fundamentally, the company reported strong 2025 results with revenue of $58.74B and net income of $10.23B, though a recent $1.5B licensing deal for a lung cancer drug highlights ongoing pipeline investments. Analyst sentiment is mixed with 47.5% buy ratings but recent downgrades from firms like HSBC citing trial setbacks.
The outlook balances robust financials against pipeline execution risks. Revenue growth and high margins support valuation, but the Wainua failure raises concerns about future catalysts. Investors should weigh the company's strong cash flow and market position against clinical trial volatility and potential legal investigations. Near-term price action may hinge on Q2 2026 earnings due July 27, 2026.
TSLL is trading at $12.27, down 6.26% today amid bearish technical signals. The stock faces selling pressure with all 13 moving averages indicating bearish momentum while oscillators remain neutral. Recent news highlights derivative-based ETF strategies and Tesla earnings implications. The company has a future dividend scheduled for June 2026.
The technical outlook appears challenging with strong bearish momentum, though the stock is trading near key support at $12. Fundamental analysis is limited due to unavailable financial ratios. Investors face volatility risks from the leveraged ETF structure and dependency on underlying Tesla performance.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AstraZeneca plc
A merger between Astra of Sweden and Zeneca Group of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across several major therapeutic classes, including gastrointestinal, diabetes, cardiovascular, respiratory, cancer, and immunology. The majority of sales come from international markets with the United States representing close to one third of its sales.
Read more on AZN →About Direxion Daily TSLA Bull 2X Shares
TSLL provides 200% of the daily performance of Tesla, Inc. (TSLA). It uses swaps and financial derivatives to achieve its 2x leverage, making it a high-volatility tool for tactical trading rather than long-term investment due to daily resets.
Read more on TSLL →
